RT Journal Article
SR Electronic
T1 Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 9
OP 28
DO 10.1183/09031936.00190310
VO 39
IS 1
A1 T. Berghmans
A1 F. Pasleau
A1 M. Paesmans
A1 Y. Bonduelle
A1 J. Cadranel
A1 I. Cs Toth
A1 C. Garcia
A1 V. Giner
A1 S. Holbrechts
A1 J.J. Lafitte
A1 J. Lecomte
A1 I. Louviaux
A1 E. Markiewicz
A1 A.P. Meert
A1 M. Richez
A1 M. Roelandts
A1 A. Scherpereel
A1 Ch. Tulippe
A1 P. Van Houtte
A1 P. Van Schil
A1 C. Wachters
A1 V. Westeel
A1 J.P. Sculier
YR 2012
UL http://erj.ersjournals.com/content/39/1/9.abstract
AB The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature with experts on these questions, it can be concluded that overall survival is still the best criterion for predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if not surrogates, for survival, despite limitations in their potential application: these include time to progression, progression-free survival, objective response, local control after radiotherapy, downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer.